enGene Holdings Inc. (ENGN)
NASDAQ: ENGN · IEX Real-Time Price · USD
12.98
-1.21 (-8.53%)
At close: May 17, 2024, 4:00 PM
12.86
-0.12 (-0.92%)
After-hours: May 17, 2024, 4:41 PM EDT

Company Description

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs.

Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.

The company was founded in 2023 and is based in Saint-Laurent, Canada.

enGene Holdings Inc.
Country Canada
Founded 1999
Industry Biotechnology
Sector Healthcare
Employees 31
CEO Jason D. Hanson Esq., J.D.

Contact Details

Address:
4868 Rue Levy, Suite 220
Saint-laurent, A8 H4R 2P1
Quebec, Canada
Phone (514) 332-4888
Website engene.com

Stock Details

Ticker Symbol ENGN
Exchange NASDAQ
Fiscal Year November - October
Reporting Currency USD
CIK Code 0001980845
CUSIP Number 46429B226
ISIN Number CA29286M1059
SIC Code 2836

Key Executives

Name Position
Jason D. Hanson Esq., J.D. Chief Executive Officer and Director
Dr. Alex Nichols Ph.D. President and Chief Operating Officer
Dr. James C. Sullivan M.Sc., Ph.D. Chief Scientific Officer
Dr. Anthony T. Cheung Ph.D. Co-Founder and Chief Technology Officer
John C. Brown D.Sc., FRSC, Ph.D. Co-Founder and Member of Scientific Advisory Board
David Ryan Daws Chief Financial Officer and Head of Business Development
Lee G. Giguere Chief Legal Officer and Corporate Secretary
Sharon Tan Vice President of Project Management and Head of Program Management
Dr. Richard P. Bryce MBChB, MFPM, MRCGP Chief Medical Officer
Paul Erickson Non-Executive Director

Latest SEC Filings

Date Type Title
May 15, 2024 424B3 Prospectus
May 15, 2024 8-K Current Report
Apr 25, 2024 424B3 Prospectus
Apr 18, 2024 ARS Filing
Apr 18, 2024 DEF 14A Other definitive proxy statements
Mar 12, 2024 424B3 Prospectus
Mar 11, 2024 10-Q Quarterly Report
Mar 11, 2024 8-K Current Report
Mar 5, 2024 EFFECT Notice of Effectiveness
Mar 5, 2024 424B3 Prospectus